Myeloid cells in vascular dementia and Alzheimer’s disease: Possible therapeutic targets?

García-Culebras A, Cuartero MI, Peña-Martínez C et al. Br J Pharmacol. 2024 Mar;181(6):777-798. doi: 10.1111/bph.16159. Epub 2023 Jul 7. PMID: 37282844

Abstract: Growing evidence supports the suggestion that the peripheral immune system playsa role in different pathologies associated with cognitive impairment, such as vasculardementia (VD) or Alzheimer’s disease (AD). The aim of this review is to summarize,within the peripheral immune system, the implications of different types of myeloidcells in AD and VD, with a special focus on post-stroke cognitive impairment anddementia (PSCID). We will review the contributions of the myeloid lineage, fromperipheral cells (neutrophils, platelets, monocytes and monocyte-derived macro-phages) to central nervous system (CNS)-associated cells (perivascular macrophagesand microglia). Finally, we will evaluate different potential strategies for pharmacolog-ical modulation of pathological processes mediated by myeloid cell subsets, with anemphasis on neutrophils, their interaction with platelets and the process of immuno-thrombosis that triggers neutrophil-dependent capillary stall and hypoperfusion, as possible effector mechanisms that may pave the way to novel therapeutic avenues tostop dementia, the epidemic of our time.

Funding: This work was supported by grants from Spanish Ministry of Scienceand Innovation (MCIN) PID2019-106581RB-I00 (MAM), from LeducqFoundation for Cardiovascular Research TNE19CVD01 (MAM, AGCand MIC) and TNE-21CVD04 (IL and MAM), from Instituto de SaludCarlos III (ISCIII) and co-financed by the European Development Regional Fund “A Way to Achieve Europe”PI20/00535 and RICORS-ICTUSRD21/0006/0001 (IL). CNIC is supported by ISCIII. The CNIC isa Severo Ochoa Center of Excellence (CEX2020-001041-S